Learn more about GLOW, our network of NLPHL experts and patient advocates, and a few of our milestones below.
To optimize the diagnosis and treatment of NLPHL through international collaboration that will allow for rigorous scientific investigations of this rare disease.
To optimize the treatment of NLPHL for every adult and child.
GLOW achieves its aims through the use of expert committees.
The GLOW Executive Committee is comprised of NLPHL experts and patient advocates from around the world who are responsible for the strategic direction and oversight of GLOW research.
GLOW research committees are comprised of NLPHL experts who design, implement, and analyze collaborative projects to address the scientific priorities of GLOW.
The GLOW Advocacy, Education, & Outreach Committee disseminates and promotes GLOW findings to key stakeholders.
Pediatric Oncologist
University of Rochester, USA
Radiation Oncologist
Stanford University, USA
Consortium Manager
University of Rochester, USA
Governance Expert
HiQ Analytics, LLC, USA
Oncologist
Stanford University, USA
Haematologist
Oxford University, UK
Radiation Oncologist
Stanford University, USA
Pediatric Oncologist
Roswell Park Cancer Institute, USA
Executive Committee
Prospective Trial Committee
University of Rochester, USA
Executive Committee
Retrospective Analyses Committee
Prospective Trial Committee
Stanford University, USA
Pathology & Translational Biology Committee
Phoenix Children’s Hospital, USA
Pathology & Translational Biology Committee
Massachusetts General Hospital, USA
Patient-Reported Outcomes Committee
University of Colorado School of Medicine, USA
Patient Advocate
USA
Pediatric Oncologist
Children’s Healthcare of Atlanta, USA
Patient Advocate
USA
Patient Advocate
USA
Oncologist
Dana-Farber Cancer Institute, USA
Pathologist
Phoenix Children’s Hospital, USA
Statistician
Mayo Clinic, USA
Radiation Oncologist
University of Colorado , USA
Radiation Oncologist
BC Cancer Vancouver, Canada
Early Career Investigator
University of Colorado, USA
Pathologist
Stanford University, USA
Early Career Investigator
Children’s Hospital London Health Sciences Centre, Canada
Statistician
St. Jude Children’s Research Hospital, USA
Radiation Oncologist
Oxford University, UK
Pathologist
Amsterdam UMC, VU University Medical Center, The Netherlands
Radiation Oncologist
Medical University of Vienna, Austria
Oncologist
University Hospital of Cologne, Germany
Pathologist
Goethe University Frankfurt, Germany
Patient Advocate
Switzerland
Early Career Investigator
Justus-Liebig University Gießen, Germany
Early Career Investigator
University of Padova, Italy
Statistician
University College London, UK
Pediatric Oncologist
Justus-Liebig University Gießen, Germany
Pediatric Oncologist
Hospital de Câncer Infantojuvenil de Barretos, Brazil
Oncologist
Peter MacCallum Cancer Centre, Australia
Early Career Investigator
Instituto Alexander Fleming, Argentina
Radiation Oncologist
Peter MacCallum Cancer Centre, Australia
Pathologist
Universidade Federal do Rio de Janeiro, Brazil
Pediatric Oncologist
Monash Children’s Hospital, Australia
Pathologist
Concord Clinical School, Concord Hospital, University of Sydney, Australia
Dr. Jamie Flerlage approaches international pediatric research groups about joining forces to revive NLPHL research via an international consortium.
Dr. Michael Binkley begins building the largest international cohort of data from adult patients with NLPHL.
GLOW is formally established as a joint effort between pediatric and adult cooperative research groups around the world to study NLPHL and establish a standard of care across the age continuum.
Dr. Michael Binkley and GLOW collaborators publish Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG, which presents the data from the cohort to date (559 patients ages 16 and older) diagnosed with with low-stage NLPHL.
GLOW Pathology & Translational Biology Committee launches.
Drs Andrea Lo and Ajay Major and GLOW collaborators publish Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW), which provided evidence of the significant variability in practice patterns for management of NLPHL among global physicians. This study clarified the international resources that would be needed to establish a standard of care treatment regimen to prevent the over-treatment of patients with NLPHL and to reduce avoidable toxicities of unnecessarily aggressive treatment regimens.
The GLOW Executive Committee, Patient-Reported Outcomes Committee, and Prospective Clinical Trial Committee launch.
Members of the GLOW Executive Committee present on GLOW work to date at major conferences including Congresso SLAOP/ SOBOPE, SIOPE, ICML, ISCAYAHL, and ASCP.
Patient advocates join the GLOW Executive Committee.
Drs. Michael Binkley and Jamie Flerlage and GLOW collaborators publish International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma, an international retrospective study of 2,243 patients of all ages across 38 contributing institutions who were diagnosed with NLPHL of all stages. Clinical and pathologic factors of NLPHL were assessed and used to develop a lymphocyte-predominant international prognostic score (LP-IPS), which allows for identification of low-risk patients in whom de-intensification of therapy should be further studied.
GLOW’s Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHLPRO) study opens in North America.
The Advocacy, Education, and Outreach Committee launches.
The GLOW Executive Committee pilots its Publication Policy and Project Request Application form.
The Suzi Birz Commitment to Collaboration Award was initiated in October 2022 at the 1st GLOW Summit to celebrate GLOW members’ dedication to global collaboration. The award is named in honor of GLOW’s founding consortium manager and governance expert, Suzi Birz, MScMMI, Life FHIMSS.
2022 Suzi Birz, MScMI, FHIMSS
The Global nLPHL One Working Group is committed to improving outcomes for all patients diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma.
Interested in joining GLOW? Complete our Tell Us About You form!